Radioactive antibody trial offers hope for tough bladder cancers
NCT ID NCT07260162
Summary
This first-in-human study is testing a new treatment called ATO-101™ for people with a specific type of bladder cancer that has not responded to standard therapies. The treatment involves placing a radioactive antibody directly into the bladder to target and destroy cancer cells while trying to spare healthy tissue. The main goal of this early trial is to find the safest and most effective dose for 24 patients before larger studies can begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire Atlantique, 44800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.